Matthew J Budoff, MD
Internal Medicine · Torrance
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
- Since medical school
- 36 years
- George Washington University School of Medicine, 1990
Offices
4 locations · Prohealth Partners, A Medical Group · United Medical Imaging Healthcare Inc · Clear Heart-Loveland LLC · Prairie Du Chien Memorial Hospital Association Inc
Hospitals listed: Crossing Rivers Health Medical Center · Lac/Harbor-UCLA Med Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Budoff’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G72496 · Current
Licensed to practise in California · since 1991 · expires 2027-08-31 · George Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Cardiovascular Disease
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Crossing Rivers Health Medical CenterPrairie Du Chien, WICritical Access Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPatients rate it 5 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsNo measure marked better or worse than the national rate
- Lac/Harbor-UCLA Med CenterTorrance, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Los Angeles County Department of Health Services, which runs 4 hospitalsPatients rate it 2 of 5 · 61% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.4 (1.03 to 1.76), Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 6.19 (3.89 to 8.48) · 636 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.418, Oct 2024 – Sep 2025
See every measure and the patient survey for Crossing Rivers Health Medical Center
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 1 better, 2 the same, 1 worse of 4 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for heart failure patientsComplications and deaths | 11.4 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 64 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.2 · 150 cases | None | Jul 2024 – Jun 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.6 · 33 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.2 · 68 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 60 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.1 (10.4 to 19) · 214 cases | No different | Jan 2022 – Dec 2024 |
What patients said (107 patients answered, 29% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 5 |
| Discharge information | 5 |
| Overall hospital rating | 5 |
| Quietness | 5 |
| Recommend hospital | 5 |
| Room was "always" clean | 92% |
| Nurses "always" communicated well | 89% |
| Doctors "always" communicated well | 84% |
| Staff "always" explained | 79% |
| Yes, staff "did" give patients this information | 91% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 81% |
| Doctors "always" listened carefully | 83% |
| Doctors "always" treated them with courtesy and respect | 88% |
| Patients who gave a rating of "9" or "10" (high) | 81% |
| Staff "always" explained new medications | 90% |
| Nurses "always" explained things so they could understand | 86% |
| Nurses "always" listened carefully | 88% |
| Nurses "always" treated them with courtesy and respect | 94% |
| "Always" quiet at night | 73% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 67% |
| Yes, staff "did" give patients information about possible symptoms | 92% |
See every measure and the patient survey for Lac/Harbor-UCLA Med Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 6 the same, 1 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.4 (1.03 to 1.76) | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 6.19 (3.89 to 8.48) · 636 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.418 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.72 (0.69 to 2.74) · 510 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 177.34 (124.5 to 230.19) · 54 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.3 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.6 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.8 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.6 · 110 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 15.3 · 73 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 1,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,023 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 3,035 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.25) · 189 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.16 (0.6 to 3.72) · 621 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 16.15 (7.82 to 24.48) · 207 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.39 (3.47 to 11.31) · 207 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.66 (1.17 to 4.15) · 134 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.69 (0 to 1.46) · 2,400 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.138 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.458 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.312 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.093 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.2 · 113 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23.1 · 190 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.6 · 134 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.2 · 122 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.4 · 162 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.4 (5 to 10.8) · 115 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.2 to 17.3) · 115 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 93 cases | None | Jul 2023 – Jun 2025 |
What patients said (1,594 patients answered, 15% of those asked)
| Cleanliness | 1 |
| Nurse communication | 1 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 53% |
| Nurses "always" communicated well | 68% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 60% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 64% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 75% |
| "Always" quiet at night | 30% |
| "YES", patients would definitely recommend the hospital | 61% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$674,975
Medicare paid this office $674,975 for 1,752 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Ct scan of blood vessels and grafts of heart with contrast | 1,112 | $290,595 | $256 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 220 | $191,896 | $868 |
| Preparation, transmission and computerized analysis of ct angiography data on plaque in heart arteries, with review, interpretation, and report | 31 | $44,583 | $1,438 |
| Ct scan of heart with evaluation of blood vessel calcium | 471 | $42,557 | $90 |
| Ct scan of abdomen and pelvis before and after contrast | 42 | $13,790 | $321 |
See all 21 services
| Ct scan of blood vessels and grafts of heart with contrast | 1,112 | $290,595 | $256 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 220 | $191,896 | $868 |
| Preparation, transmission and computerized analysis of ct angiography data on plaque in heart arteries, with review, interpretation, and report | 31 | $44,583 | $1,438 |
| Ct scan of heart with evaluation of blood vessel calcium | 471 | $42,557 | $90 |
| Ct scan of abdomen and pelvis before and after contrast | 42 | $13,790 | $321 |
| Ct scan for measuring calcium and other minerals in bone | 106 | $12,641 | $118 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,162 | $8,914 | $0 |
| Ct scan of chest without contrast | 61 | $7,576 | $120 |
| Return visit (30+ min) | 54 | $7,399 | $100 |
| New patient visit (45+ min) | 47 | $6,839 | $146 |
| Ct scan of blood vessels of chest with contrast | 27 | $5,828 | $208 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 27 | $5,139 | $184 |
| Ct scan head or brain with contrast | 39 | $3,630 | $93 |
| Ct scan of blood vessels of neck with contrast | 20 | $3,449 | $172 |
| Ct scan of chest before and after contrast | 18 | $3,448 | $181 |
| Ct scan of abdomen and pelvis without contrast | 23 | $3,324 | $145 |
| Ct scan of pelvis before and after contrast | 19 | $2,761 | $145 |
| Ct scan of blood vessels of lower leg with contrast | 11 | $2,703 | $246 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 38 | $1,651 | $42 |
| Short return visit (20+ min) | 16 | $1,279 | $80 |
| Injection of drug or substance into vein | 14 | $479 | $34 |
Who their Medicare patients are
1,752 Original Medicare patients in 2024. Average age 73 · Under 65 2% · 85 and older 6% · Women 51% · Also on Medicaid 8% · Health risk score 0.86. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 73% · Coronary heart disease 58% · Diabetes 32% · Chronic kidney disease 16% · Atrial fibrillation 16% · Cancer 15% · Heart failure 14% · Depression 13% · COPD 9% · Stroke 6% · Dementia 3%.
The office billed $3,180,154, Medicare allowed $850,435 and paid $674,975; for 88,302 services of 52 kinds; $8,915 of it was for drugs given in the office and $666,060 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,752 | 88,302 | 73 | 0.86 | $3,180,154 | $674,975 |
| 2023 | 1,613 | 81,208 | 73 | 0.92 | $2,248,762 | $533,202 |
| 2022 | 1,525 | 63,630 | 73 | 0.94 | $1,868,225 | $438,752 |
| 2021 | 1,476 | 64,213 | 73 | 0.91 | $1,471,338 | $342,430 |
| 2020 | 939 | 55,830 | 73 | 1.02 | $1,244,788 | $274,247 |
| 2019 | 1,190 | 57,746 | 72 | 1.00 | $1,317,427 | $286,773 |
| 2018 | 915 | 42,623 | 72 | 0.96 | $1,122,723 | $228,929 |
| 2017 | 722 | 32,504 | 72 | 1.01 | $914,784 | $183,909 |
| 2016 | 558 | 23,507 | 72 | 1.01 | $696,136 | $122,675 |
| 2015 | 622 | 27,878 | 72 | 1.35 | $827,680 | $151,507 |
| 2014 | 506 | 28,785 | 72 | 1.41 | $794,244 | $147,054 |
| 2013 | 444 | 28,184 | 72 | 1.38 | $835,730 | $157,071 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Ct scan of blood vessels and grafts of heart with contrast | 1,065 | $275,857 | $259 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 142 | $134,071 | $931 |
| Ct scan of heart with evaluation of blood vessel calcium | 402 | $37,145 | $92 |
| Ct scan of abdomen and pelvis before and after contrast | 59 | $19,575 | $326 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,097 | $9,153 | $0 |
| Ct scan for measuring calcium and other minerals in bone | 80 | $9,147 | $114 |
| Ct scan of chest without contrast | 59 | $7,657 | $123 |
| Return visit (30+ min) | 39 | $5,648 | $105 |
| Ct scan of blood vessels of neck with contrast | 23 | $3,898 | $169 |
| New patient visit (45+ min) | 25 | $3,248 | $130 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 14 | $2,547 | $182 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 49 | $2,362 | $48 |
| Ct scan of blood vessels of chest with contrast | 12 | $2,178 | $182 |
| Ct scan of chest before and after contrast | 11 | $1,882 | $171 |
| Ct scan of abdomen and pelvis without contrast | 14 | $1,830 | $131 |
| Injection of drug or substance into vein | 49 | $1,704 | $35 |
| Short return visit (20+ min) | 13 | $1,216 | $76 |
| Ct scan head or brain with contrast | 11 | $922 | $84 |
| Unclassified drugs | 29 | $27 | None |
2022: 23 services
| Ct scan of blood vessels and grafts of heart with contrast | 820 | $212,746 | $258 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 62 | $58,733 | $932 |
| Ct scan of heart with evaluation of blood vessel calcium | 548 | $49,271 | $90 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, analysis of fluid dynamics | 19 | $17,422 | $917 |
| Ct scan of abdomen and pelvis before and after contrast | 44 | $14,868 | $338 |
| Ct scan for measuring calcium and other minerals in bone | 126 | $13,886 | $110 |
| Ct scan of chest without contrast | 66 | $7,903 | $120 |
| Return visit (30+ min) | 49 | $7,532 | $105 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 39 | $7,176 | $175 |
| Ct scan of blood vessels of neck with contrast | 32 | $6,038 | $183 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 861 | $5,705 | $0 |
| Ct scan of chest before and after contrast | 26 | $4,611 | $177 |
| Ct scan of abdomen and pelvis without contrast | 23 | $3,574 | $155 |
| New patient visit (45+ min) | 25 | $3,320 | $133 |
| Injection of drug or substance into vein | 85 | $3,135 | $37 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 55 | $2,633 | $46 |
| Ct scan of blood vessels of chest with contrast | 12 | $2,296 | $191 |
| Short return visit (20+ min) | 14 | $1,675 | $80 |
| Long return visit (40+ min) | 11 | $1,447 | $121 |
| Ct scan head or brain with contrast | 14 | $1,320 | $94 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, anatomical data review | 18 | $574 | $32 |
| Injection of additional new drug or substance into vein | 24 | $359 | $15 |
| Unclassified drugs | 30 | $18 | None |
2021: 20 services
| Ct scan of blood vessels and grafts of heart with contrast | 721 | $191,639 | $265 |
| Ct scan of heart with evaluation of blood vessel calcium | 585 | $54,981 | $94 |
| Ct scan for measuring calcium and other minerals in bone | 161 | $17,575 | $109 |
| Ct scan of blood vessels of neck with contrast | 54 | $9,677 | $179 |
| Ct scan of abdomen and pelvis before and after contrast | 37 | $9,097 | $246 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 31 | $5,833 | $182 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 766 | $5,832 | $0 |
| Return visit (30+ min) | 39 | $5,592 | $102 |
| Ct scan of chest without contrast | 44 | $5,204 | $118 |
| Ct scan of chest before and after contrast | 27 | $4,922 | $176 |
| Injection of drug or substance into vein | 120 | $4,692 | $39 |
| Ct scan of abdomen and pelvis with contrast | 12 | $4,010 | $267 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 58 | $2,960 | $50 |
| Ct scan of abdomen and pelvis without contrast | 17 | $2,852 | $168 |
| Ct scan of blood vessels of chest with contrast | 14 | $2,846 | $203 |
| New patient visit (45+ min) | 17 | $2,553 | $150 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, anatomical data review | 22 | $586 | $27 |
| Injection of additional new drug or substance into vein | 32 | $507 | $16 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $472 | $26 |
| Unclassified drugs | 57 | $56 | None |
2020: 22 services
| Ct scan of blood vessels and grafts of heart with contrast | 462 | $124,003 | $266 |
| Ct scan of heart with evaluation of blood vessel calcium | 309 | $27,263 | $88 |
| Ct scan of blood vessels of neck with contrast | 129 | $22,371 | $173 |
| Ct scan for measuring calcium and other minerals in bone | 120 | $12,895 | $107 |
| 3d radiographic procedure with computerized image postprocessing | 177 | $12,650 | $66 |
| Ct scan of chest without contrast | 55 | $7,561 | $133 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 34 | $7,093 | $182 |
| Ct scan of blood vessels of chest with contrast | 32 | $6,796 | $206 |
| Ct scan of abdomen and pelvis with contrast | 15 | $6,610 | $275 |
| Ct scan of abdomen and pelvis before and after contrast | 18 | $6,165 | $343 |
| Return visit (30+ min) | 43 | $5,384 | $88 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 507 | $4,705 | $0 |
| New patient visit (45+ min) | 33 | $4,599 | $139 |
| Ct scan of abdomen and pelvis without contrast | 28 | $4,483 | $160 |
| Ct scan of chest before and after contrast | 16 | $3,239 | $202 |
| Injection of drug or substance into vein | 66 | $2,443 | $36 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 43 | $2,404 | $55 |
| Short return visit (20+ min) | 17 | $1,423 | $68 |
| Test for detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antibody, qualitative or semiquantitative | 18 | $814 | $45 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $486 | $27 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, anatomical data review | 11 | $135 | $12 |
| Unclassified drugs | 58 | $60 | None |
2019: 22 services
| Ct scan of blood vessels and grafts of heart with contrast | 505 | $139,167 | $274 |
| Ct scan of heart with evaluation of blood vessel calcium | 504 | $37,365 | $74 |
| Ct scan for measuring calcium and other minerals in bone | 216 | $17,876 | $83 |
| Ct scan of chest without contrast | 68 | $9,424 | $127 |
| Ct scan of blood vessels of chest with contrast | 36 | $9,180 | $248 |
| 3d radiographic procedure with computerized image postprocessing | 123 | $7,761 | $63 |
| Ct scan of abdomen and pelvis with contrast | 12 | $7,508 | $268 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 28 | $5,969 | $181 |
| Ct scan of abdomen and pelvis without contrast | 34 | $5,542 | $163 |
| Ct scan of blood vessels of neck with contrast | 26 | $5,016 | $193 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 542 | $4,943 | $0 |
| Ct scan of chest before and after contrast | 24 | $4,761 | $190 |
| Return visit (30+ min) | 34 | $4,316 | $83 |
| Ct scan of chest with contrast | 14 | $3,828 | $128 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 63 | $3,260 | $51 |
| Injection of drug or substance into vein | 89 | $3,155 | $34 |
| Ct scan of soft tissue of neck before and after contrast | 18 | $2,707 | $150 |
| Short return visit (20+ min) | 19 | $1,833 | $56 |
| New patient visit (45+ min) | 12 | $1,643 | $137 |
| New patient visit (30+ min) | 21 | $1,614 | $77 |
| Injection of additional new drug or substance into vein | 25 | $353 | $14 |
| Unclassified drugs | 66 | $51 | None |
2018: 16 services
| Ct scan of blood vessels and grafts of heart with contrast | 371 | $118,622 | $319 |
| Ct scan of heart with evaluation of blood vessel calcium | 390 | $29,422 | $75 |
| Ct scan for measuring calcium and other minerals in bone | 213 | $17,579 | $83 |
| Ct scan of chest without contrast | 72 | $9,083 | $121 |
| Ct scan of blood vessels of chest with contrast | 30 | $7,264 | $242 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 24 | $5,960 | $175 |
| Ct scan of blood vessels of neck with contrast | 21 | $5,192 | $236 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 402 | $3,913 | $0 |
| Ct scan of chest before and after contrast | 20 | $3,778 | $189 |
| Return visit (30+ min) | 24 | $3,681 | $78 |
| Injection of drug or substance into vein | 80 | $3,384 | $39 |
| Ct scan of abdomen and pelvis without contrast | 20 | $3,346 | $159 |
| Short return visit (20+ min) | 21 | $2,353 | $56 |
| New patient visit (30+ min) | 19 | $1,577 | $83 |
| Injection of additional new drug or substance into vein | 21 | $352 | $15 |
| Unclassified drugs | 47 | $36 | None |
2017: 12 services
| Ct scan of blood vessels and grafts of heart with contrast | 292 | $95,365 | $327 |
| Ct scan of heart with evaluation of blood vessel calcium | 285 | $20,070 | $70 |
| Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 215 | $14,381 | $1 |
| Ct scan for measuring calcium and other minerals in bone | 151 | $11,766 | $78 |
| Ct scan of chest without contrast | 70 | $9,336 | $130 |
| Return visit (30+ min) | 39 | $4,947 | $80 |
| Injection of drug or substance into vein | 91 | $4,340 | $48 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 19 | $3,657 | $174 |
| Ct scan of abdomen and pelvis without contrast | 23 | $2,910 | $127 |
| Short return visit (20+ min) | 19 | $1,302 | $48 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 95 | $921 | $0 |
| Unclassified drugs | 40 | $23 | None |
2016: 12 services
| Ct scan of blood vessels and grafts of heart with contrast | 193 | $58,668 | $304 |
| Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 211 | $13,958 | $1 |
| Ct scan of heart with evaluation of blood vessel calcium | 256 | $8,497 | $33 |
| Ct scan of chest without contrast | 50 | $6,743 | $132 |
| Return visit (30+ min) | 28 | $5,778 | $81 |
| Ct scan for measuring calcium and other minerals in bone | 56 | $4,518 | $81 |
| Injection of drug or substance into vein | 84 | $4,012 | $48 |
| Ct scan of abdomen and pelvis without contrast | 24 | $2,960 | $123 |
| Ct scan of blood vessels of chest with contrast | 12 | $2,246 | $187 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 11 | $2,121 | $193 |
| Short return visit (20+ min) | 18 | $1,368 | $59 |
| Unclassified drugs | 84 | $51 | None |
2015: 19 services
| Ct scan of blood vessels and grafts of heart with contrast | 207 | $60,676 | $292 |
| Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 229 | $18,305 | $1 |
| Ct scan of heart with evaluation of blood vessel calcium | 227 | $10,782 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $8,861 | $84 |
| Injection of drug or substance into vein | 151 | $7,519 | $50 |
| Return visit (30+ min) | 37 | $6,736 | $84 |
| Ct scan of chest without contrast | 32 | $4,987 | $142 |
| Ct scan of blood vessels of chest with contrast | 19 | $4,401 | $232 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,664 | $167 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 14 | $2,788 | $199 |
| Ct scan of abdomen and pelvis without contrast | 17 | $2,041 | $120 |
| Ct scan of soft tissue of neck before and after contrast | 11 | $2,033 | $185 |
| Ct scan for measuring calcium and other minerals in bone | 20 | $1,616 | $81 |
| Short return visit (20+ min) | 21 | $1,126 | $40 |
| Injection of additional new drug or substance into vein | 52 | $1,003 | $18 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 54 | $661 | $7 |
| Short return visit (20+ min) | 14 | $623 | $42 |
| Unclassified drugs | 150 | $75 | None |
| Insertion of needle into vein for collection of blood sample | 13 | $47 | $3 |
2014: 17 services
| Ct scan of blood vessels and grafts of heart with contrast | 212 | $62,851 | $296 |
| Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 238 | $20,952 | $1 |
| Injection of drug or substance into vein | 156 | $7,825 | $50 |
| Ct scan of blood vessels of chest with contrast | 25 | $6,989 | $280 |
| Ct scan of heart with evaluation of blood vessel calcium | 160 | $6,715 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $5,999 | $87 |
| Short return visit (20+ min) | 38 | $5,577 | $58 |
| Ct scan of chest without contrast | 25 | $3,898 | $144 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 16 | $3,608 | $200 |
| Ct scan of abdomen and pelvis without contrast | 15 | $2,036 | $136 |
| Ct scan for measuring calcium and other minerals in bone | 16 | $1,846 | $115 |
| New patient visit (30+ min) | 15 | $1,291 | $86 |
| Injection of additional new drug or substance into vein | 51 | $981 | $19 |
| Short return visit (20+ min) | 13 | $515 | $40 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 26 | $364 | $7 |
| Unclassified drugs | 153 | $112 | None |
| Insertion of needle into vein for collection of blood sample | 15 | $50 | $3 |
2013: 16 services
| Ct scan of blood vessels and grafts of heart with contrast | 219 | $72,557 | $331 |
| Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 249 | $19,903 | $1 |
| Ct scan of blood vessels of chest with contrast | 22 | $7,348 | $294 |
| Ct scan of heart with evaluation of blood vessel calcium | 109 | $6,932 | $64 |
| Ct scan of chest without contrast | 23 | $4,006 | $167 |
| Short return visit (20+ min) | 31 | $3,455 | $56 |
| Return visit (30+ min) | 26 | $3,241 | $85 |
| Ct scan of abdomen and pelvis without contrast | 13 | $2,032 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,024 | $72 |
| Injection of drug or substance into vein | 35 | $1,788 | $51 |
| Ct scan for measuring calcium and other minerals in bone | 17 | $1,642 | $97 |
| New patient visit (30+ min) | 15 | $1,376 | $92 |
| Short return visit (20+ min) | 13 | $535 | $41 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 21 | $212 | $6 |
| Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram | 12 | $17 | None |
| Unclassified drugs | 25 | $12 | None |
Drugs they prescribed that Part D paid
$57,738
Pharmacies billed $57,738 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 253) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
191 generic and fewer than 11 brand-name prescriptions · $57,738 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Repatha Sureclick | 21 | $18,573 | $884 |
| Nexletol | 13 | $5,048 | $388 |
| Rosuvastatin | 40 | $530 | $13 |
| Atorvastatin | 22 | $263 | $12 |
| Metoprolol | 19 | $139 | $7 |
See all 7 drugs
| Repatha Sureclick | 21 | $18,573 | $884 |
| Nexletol | 13 | $5,048 | $388 |
| Rosuvastatin | 40 | $530 | $13 |
| Atorvastatin | 22 | $263 | $12 |
| Metoprolol | 19 | $139 | $7 |
| Losartan | 18 | $111 | $6 |
| Amlodipine Besylate | 12 | $66 | $6 |
Year by year
| 2024 | 253 | 56 | 0% (0) | None | $57,738 |
| 2023 | 266 | 49 | 0% (0) | 23% | $65,073 |
| 2022 | 291 | 49 | 0% (0) | None | $44,715 |
| 2021 | 339 | 40 | 0% (0) | 10% | $29,750 |
| 2020 | 378 | 44 | 0% (0) | 11% | $38,005 |
| 2019 | 387 | 37 | None | None | $31,343 |
| 2018 | 379 | 28 | None | 15% | $31,791 |
| 2017 | 420 | 32 | 0% (0) | 26% | $35,949 |
| 2016 | 388 | 30 | None | 22% | $29,218 |
| 2015 | 394 | 31 | 0% (0) | 15% | $25,674 |
| 2014 | 403 | 37 | None | 17% | $20,862 |
| 2013 | 389 | 31 | None | 15% | $15,129 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Xarelto | 13 | $21,754 | $1,673 |
| Entresto | 12 | $13,943 | $1,162 |
| Repatha Sureclick | 13 | $8,690 | $668 |
| Rosuvastatin | 35 | $858 | $25 |
| Atorvastatin | 41 | $563 | $14 |
| Metoprolol | 27 | $271 | $10 |
| Amlodipine Besylate | 15 | $113 | $8 |
2022: 7 drugs
| Rosuvastatin | 24 | $616 | $26 |
| Amlodipine Besylate | 44 | $422 | $10 |
| Atorvastatin | 27 | $379 | $14 |
| Metoprolol | 29 | $355 | $12 |
| Losartan | 15 | $115 | $8 |
| Lisinopril | 11 | $72 | $7 |
| Ramipril | 11 | $58 | $5 |
2021: 13 drugs
| Repatha Sureclick | 13 | $6,521 | $502 |
| Propranolol Hcl Er | 13 | $3,375 | $260 |
| Primidone | 14 | $819 | $58 |
| Ezetimibe | 16 | $598 | $37 |
| Rosuvastatin | 20 | $321 | $16 |
| Buspirone | 12 | $265 | $22 |
| Metoprolol | 20 | $210 | $11 |
| Ramipril | 29 | $173 | $6 |
| Montelukast | 13 | $151 | $12 |
| Pravastatin | 12 | $128 | $11 |
| Amlodipine Besylate | 30 | $126 | $4 |
| Carvedilol | 15 | $119 | $8 |
| Losartan | 13 | $114 | $9 |
2020: 13 drugs
| Repatha Sureclick | 16 | $7,319 | $457 |
| Propranolol Hcl Er | 12 | $3,784 | $315 |
| Ezetimibe | 21 | $956 | $46 |
| Primidone | 14 | $884 | $63 |
| Valsartan | 12 | $337 | $28 |
| Pravastatin | 15 | $292 | $19 |
| Rosuvastatin | 14 | $211 | $15 |
| Tamsulosin | 15 | $171 | $11 |
| Ramipril | 17 | $166 | $10 |
| Losartan | 22 | $154 | $7 |
| Amlodipine Besylate | 37 | $122 | $3 |
| Atorvastatin | 11 | $122 | $11 |
| Atenolol | 14 | $32 | $2 |
2019: 17 drugs
| Eliquis | 11 | $5,230 | $475 |
| Propranolol Hcl Er | 17 | $3,480 | $205 |
| Primidone | 13 | $762 | $59 |
| Ezetimibe | 12 | $292 | $24 |
| Buspirone | 11 | $287 | $26 |
| Pravastatin | 12 | $242 | $20 |
| Rosuvastatin | 11 | $165 | $15 |
| Amlodipine Besylate | 41 | $163 | $4 |
| Furosemide | 19 | $163 | $9 |
| Benazepril | 11 | $155 | $14 |
| Ramipril | 16 | $150 | $9 |
| Carvedilol | 14 | $130 | $9 |
| Tamsulosin | 15 | $128 | $9 |
| Spironolactone | 14 | $112 | $8 |
| Losartan | 15 | $76 | $5 |
| Atenolol | 13 | $30 | $2 |
| Valsartan | 11 | $25 | $2 |
2018: 11 drugs
| Niacin Er | 12 | $3,750 | $312 |
| Propranolol Hcl Er | 21 | $2,415 | $115 |
| Ezetimibe | 18 | $760 | $42 |
| Primidone | 14 | $667 | $48 |
| Pravastatin | 13 | $317 | $24 |
| Amlodipine Besylate | 32 | $199 | $6 |
| Ramipril | 16 | $157 | $10 |
| Carvedilol | 22 | $98 | $4 |
| Losartan | 16 | $77 | $5 |
| Atenolol | 13 | $65 | $5 |
| Omeprazole | 11 | $61 | $6 |
2017: 16 drugs
| Xarelto | 22 | $10,894 | $495 |
| Propranolol Hcl Er | 25 | $2,645 | $106 |
| Niacin Er | 12 | $2,095 | $175 |
| Metolazone | 12 | $569 | $47 |
| Metoprolol | 14 | $521 | $37 |
| Isosorbide Mononitrate Er | 22 | $476 | $22 |
| Primidone | 11 | $447 | $41 |
| Pravastatin | 13 | $431 | $33 |
| Atorvastatin | 18 | $204 | $11 |
| Ramipril | 13 | $134 | $10 |
| Losartan | 27 | $133 | $5 |
| Atenolol | 18 | $91 | $5 |
| Carvedilol | 11 | $82 | $7 |
| Amlodipine Besylate | 17 | $77 | $5 |
| Pantoprazole | 13 | $68 | $5 |
| Furosemide | 14 | $61 | $4 |
2016: 13 drugs
| Zetia | 12 | $3,300 | $275 |
| Propranolol Hcl Er | 23 | $2,389 | $104 |
| Niacin Er | 15 | $1,860 | $124 |
| Metoprolol | 12 | $590 | $49 |
| Atorvastatin | 24 | $567 | $24 |
| Isosorbide Mononitrate Er | 19 | $422 | $22 |
| Ramipril | 14 | $402 | $29 |
| Primidone | 11 | $390 | $35 |
| Amlodipine Besylate | 29 | $297 | $10 |
| Pravastatin | 12 | $264 | $22 |
| Losartan | 27 | $160 | $6 |
| Atenolol | 30 | $138 | $5 |
| Furosemide | 15 | $38 | $3 |
2015: 16 drugs
| Niacin Er | 22 | $5,344 | $243 |
| Eliquis | 11 | $3,562 | $324 |
| Zetia | 13 | $3,004 | $231 |
| Propranolol Hcl Er | 23 | $2,436 | $106 |
| Atorvastatin | 17 | $633 | $37 |
| Ramipril | 12 | $362 | $30 |
| Pravastatin | 17 | $304 | $18 |
| Primidone | 13 | $283 | $22 |
| Isosorbide Mononitrate Er | 11 | $236 | $21 |
| Amlodipine Besylate | 26 | $207 | $8 |
| Atenolol | 24 | $154 | $6 |
| Losartan | 23 | $138 | $6 |
| Amitriptyline | 12 | $128 | $11 |
| Spironolactone | 22 | $120 | $5 |
| Carvedilol | 14 | $62 | $4 |
| Furosemide | 12 | $24 | $2 |
2014: 13 drugs
| Niacin Er | 17 | $3,868 | $228 |
| Propranolol Hcl Er | 22 | $2,304 | $105 |
| Metoprolol | 14 | $824 | $59 |
| Pravastatin | 32 | $694 | $22 |
| Felodipine Er | 11 | $645 | $59 |
| Losartan | 35 | $275 | $8 |
| Amlodipine Besylate | 22 | $190 | $9 |
| Benazepril | 16 | $162 | $10 |
| Carvedilol | 13 | $146 | $11 |
| Atenolol | 15 | $112 | $7 |
| Metoprolol | 12 | $104 | $9 |
| Amitriptyline | 12 | $70 | $6 |
| Simvastatin | 11 | $52 | $5 |
2013: 12 drugs
| Diovan | 11 | $2,032 | $185 |
| Metoprolol | 14 | $906 | $65 |
| Amlodipine Besylate-Benazepril | 12 | $644 | $54 |
| Pravastatin | 25 | $435 | $17 |
| Cartia Xt | 12 | $242 | $20 |
| Lisinopril | 19 | $239 | $13 |
| Losartan | 20 | $226 | $11 |
| Benazepril | 22 | $216 | $10 |
| Amlodipine Besylate | 27 | $196 | $7 |
| Metoprolol | 24 | $175 | $7 |
| Digox | 13 | $99 | $8 |
| Amitriptyline | 12 | $33 | $3 |
Money from drug and device companies
$541,709 in 2025
| 2025 | 24 | 454 | $489,349 | $541,709 |
| 2024 | 27 | 406 | $519,135 | $574,074 |
| 2023 | 24 | 385 | $358,173 | $407,316 |
| 2022 | 22 | 437 | $441,152 | $487,476 |
| 2021 | 25 | 432 | $528,119 | $558,227 |
| 2020 | 18 | 369 | $388,984 | $407,997 |
| 2019 | 22 | 662 | $576,779 | $640,390 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Heartflow | Ffrct | $99,010 | 70 payments
|
| Novo Nordisk | Wegovy | $87,918 | 43 payments
|
| Regeneron Healthcare Solutions | Evkeeza | $74,498 | 54 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $67,900 | 52 payments
|
| Lilly USA | Zepbound | $51,933 | 46 payments
|
| Amgen | Repatha | $51,853 | 60 payments
|
See all 454 published payments
| Amgen | Travel · 2025-12-24 | Repatha | $128 |
| Amgen | Meals · 2025-12-24 | Repatha | $18 |
| Novartis Pharmaceuticals | Consulting · 2025-12-23 | Leqvio | $2,700 |
| Amgen | Travel · 2025-12-23 | Repatha | $566 |
| Amgen | Consulting · 2025-12-23 | Repatha | $3,375 |
| Amgen | Consulting · 2025-12-23 | Repatha | $750 |
| Corcept Therapeutics | Paid to speak or teach · 2025-12-17 | Korlym | $4,050 |
| Corcept Therapeutics | Travel · 2025-12-17 | Korlym | $194 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-12-17 | Kerendia | $3,016 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-12-17 | Kerendia | $82 |
| Amgen | Meals · 2025-12-17 | Repatha | $125 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-15 | None | $47 |
| Ionis Pharmaceuticals | Meals · 2025-12-13 | Olezarsen | $56 |
| Ionis Pharmaceuticals | Meals · 2025-12-13 | Olezarsen | $56 |
| Ionis Pharmaceuticals | Travel · 2025-12-13 | Olezarsen | $141 |
| Ionis Pharmaceuticals | Consulting · 2025-12-13 | Olezarsen | $9,135 |
| Regeneron Healthcare Solutions | Travel · 2025-12-12 | Evkeeza | $46 |
| Regeneron Healthcare Solutions | Travel · 2025-12-12 | Evkeeza | $34 |
| Regeneron Healthcare Solutions | Travel · 2025-12-12 | Evkeeza | $5 |
| Regeneron Healthcare Solutions | Travel · 2025-12-12 | Evkeeza | $545 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-12-12 | Kerendia | $668 |
| Heartflow | Meals · 2025-12-12 | Ffrct | $32 |
| Heartflow | Paid to speak or teach · 2025-12-12 | Ffrct | $13,490 |
| Ionis Pharmaceuticals | Travel · 2025-12-12 | Olezarsen | $237 |
| Ionis Pharmaceuticals | Travel · 2025-12-12 | Olezarsen | $150 |
| Ionis Pharmaceuticals | Travel · 2025-12-12 | Olezarsen | $333 |
| Ionis Pharmaceuticals | Travel · 2025-12-12 | Olezarsen | $99 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-10 | Kerendia | $125 |
| Amgen | Paid to speak or teach · 2025-12-09 | Repatha | $2,800 |
| Heartflow | Travel · 2025-12-08 | Ffrct | $323 |
| Corcept Therapeutics | Meals · 2025-12-05 | Korlym | $77 |
| Amgen | Meals · 2025-12-04 | Repatha | $150 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-12-03 | Lokelma | $4,680 |
| Corcept Therapeutics | Meals · 2025-12-03 | Korlym | $120 |
| Corcept Therapeutics | Meals · 2025-12-03 | Korlym | $55 |
| Corcept Therapeutics | Meals · 2025-12-03 | Korlym | $29 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-03 | Kerendia | $99 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-12-02 | Kerendia | $467 |
| Ge Healthcare | Consulting · 2025-11-30 | None | $100 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-11-28 | Kerendia | $107 |
| Amgen | Paid to speak or teach · 2025-11-27 | Repatha | $2,800 |
| Amgen | Paid to speak or teach · 2025-11-27 | Repatha | $467 |
| Amgen | Travel · 2025-11-26 | Repatha | $174 |
| Heartflow | Meals · 2025-11-26 | Ffrct | $47 |
| Heartflow | Travel · 2025-11-26 | Ffrct | $34 |
| Heartflow | Paid to speak or teach · 2025-11-26 | Ffrct | $1,420 |
| Heartflow | Paid to speak or teach · 2025-11-26 | Ffrct | $9,763 |
| Heartflow | Meals · 2025-11-26 | Ffrct | $95 |
| Novartis Pharmaceuticals | Meals · 2025-11-21 | Leqvio | $28 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-11-21 | Kerendia | $4,147 |
| Amgen | Paid to speak or teach · 2025-11-20 | Repatha | $2,335 |
| Amgen | Paid to speak or teach · 2025-11-20 | Repatha | $817 |
| Amgen | Travel · 2025-11-20 | Repatha | $657 |
| Novo Nordisk | Consulting · 2025-11-19 | None | $2,355 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-11-19 | Lokelma | $207 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-19 | Lokelma | $117 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-19 | Kerendia | $150 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-11-18 | Evkeeza | $2,135 |
| Amgen | Meals · 2025-11-18 | Repatha | $105 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-11-14 | Kerendia | $2,262 |
| Heartflow | Travel · 2025-11-13 | Ffrct | $930 |
| Novartis Pharmaceuticals | Meals · 2025-11-12 | Leqvio | $125 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-11-12 | Lokelma | $4,300 |
| Amgen | Travel · 2025-11-10 | Repatha | $303 |
| Novo Nordisk | Travel · 2025-11-08 | Wegovy | $1,077 |
| Novo Nordisk | Travel · 2025-11-08 | Wegovy | $823 |
| Novo Nordisk | Meals · 2025-11-08 | Wegovy | $61 |
| Novo Nordisk | Paid to speak or teach · 2025-11-08 | Wegovy | $10,009 |
| Novo Nordisk | Travel · 2025-11-08 | Wegovy | $99 |
| Novartis Pharmaceuticals | Meals · 2025-11-08 | Leqvio | $137 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-11-08 | Jardiance | $530 |
| Heartflow | Travel · 2025-11-08 | Ffrct | $394 |
| FUKUDA DENSHI Co. | Travel · 2025-11-07 | Vs-2000 | $1,500 |
| Novo Nordisk | Meals · 2025-11-07 | Wegovy | $98 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-11-07 | Evkeeza | $6,832 |
| Novo Nordisk | Paid to speak or teach · 2025-11-06 | Wegovy | $10,009 |
| Novo Nordisk | Travel · 2025-11-06 | Wegovy | $510 |
| Novo Nordisk | Travel · 2025-11-06 | Wegovy | $823 |
| Novo Nordisk | Travel · 2025-11-06 | Wegovy | $163 |
| Novo Nordisk | Meals · 2025-11-06 | Wegovy | $25 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-11-06 | Lokelma | $4,300 |
| Invivyd | Meals · 2025-11-05 | Pemgarda | $31 |
| Cleerly | Meals · 2025-11-05 | Cleerly Ischemia | $56 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-10-31 | Lifevest | $26 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-10-30 | Lokelma | $243 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-10-30 | Lokelma | $435 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-10-30 | Lokelma | $209 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-30 | Lokelma | $134 |
| Amgen | Meals · 2025-10-30 | Repatha | $34 |
| Novo Nordisk | Consulting · 2025-10-29 | Ozempic | $2,708 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-29 | None | $50 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-29 | None | $76 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-29 | None | $59 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-29 | None | $157 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-10-29 | None | $209 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-10-29 | None | $193 |
| Heartflow | Travel · 2025-10-29 | Ffrct | $200 |
| Heartflow | Paid to speak or teach · 2025-10-29 | Ffrct | $7,810 |
| Novo Nordisk | Consulting · 2025-10-28 | Ozempic | $1,806 |
| Novo Nordisk | Consulting · 2025-10-28 | Ozempic | $2,708 |
| Amgen | Travel · 2025-10-28 | Repatha | $76 |
| Amgen | Travel · 2025-10-28 | Repatha | $244 |
| Amgen | Paid to speak or teach · 2025-10-28 | Repatha | $2,800 |
| Amgen | Paid to speak or teach · 2025-10-27 | Repatha | $467 |
| Amgen | Paid to speak or teach · 2025-10-27 | Repatha | $2,800 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-23 | Lokelma | $19 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-10-23 | Lokelma | $198 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-10-23 | Lokelma | $141 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-23 | Lokelma | $16 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-10-23 | Lokelma | $369 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-23 | Lokelma | $126 |
| Lilly USA | Paid to speak or teach · 2025-10-22 | Jardiance | $600 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-10-22 | Kerendia | $28 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-10-22 | Kerendia | $10 |
| Amgen | Meals · 2025-10-22 | Repatha | $108 |
| Cleerly | Meals · 2025-10-22 | Cleerly Ischemia | $42 |
| Amgen | Meals · 2025-10-21 | Repatha | $127 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-10-17 | Evkeeza | $3,416 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-17 | Kerendia | $3 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-10-17 | Kerendia | $169 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-10-17 | Kerendia | $9 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-10-15 | Kerendia | $5,655 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-10-10 | Kerendia | $4,147 |
| Novartis Pharmaceuticals | Meals · 2025-10-09 | Leqvio | $90 |
| Amgen | Meals · 2025-10-09 | None | $37 |
| Heartflow | Travel · 2025-10-08 | Ffrct | $377 |
| Heartflow | Travel · 2025-10-07 | Ffrct | $50 |
| Heartflow | Meals · 2025-10-07 | Ffrct | $147 |
| Abbvie | Consulting · 2025-10-06 | None | $400 |
| Heartflow | Meals · 2025-10-06 | Ffrct | $157 |
| Merck Sharp & Dohme | Travel · 2025-10-06 | None | $150 |
| Merck Sharp & Dohme | Consulting · 2025-10-06 | None | $3,520 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-10-04 | Kerendia | $3,770 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-10-04 | Kerendia | $421 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-10-04 | Kerendia | $4,147 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-02 | Kerendia | $122 |
| Amgen | Paid to speak or teach · 2025-10-02 | Repatha | $2,800 |
| Heartflow | Travel · 2025-10-01 | Ffrct | $123 |
| Heartflow | Travel · 2025-10-01 | Ffrct | $180 |
| Heartflow | Meals · 2025-09-30 | Ffrct | $146 |
| Lilly USA | Paid to speak or teach · 2025-09-29 | Jardiance | $1,200 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-09-27 | Kerendia | $270 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-09-26 | Kerendia | $225 |
| Amgen | Travel · 2025-09-26 | Repatha | $89 |
| Amgen | Paid to speak or teach · 2025-09-25 | Repatha | $2,800 |
| Heartflow | Meals · 2025-09-25 | Ffrct | $50 |
| Amgen | Meals · 2025-09-23 | Repatha | $126 |
| BridgeBio Pharma | Meals · 2025-09-20 | Attruby | $22 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-18 | Kerendia | $51 |
| Amarin Pharma | Paid to speak or teach · 2025-09-18 | Vascepa | $2,600 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-17 | Kerendia | $71 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-17 | Kerendia | $31 |
| Regeneron Healthcare Solutions | Travel · 2025-09-16 | Evkeeza | $56 |
| Heartflow | Consulting · 2025-09-15 | Ffrct | $213 |
| Heartflow | Paid to speak or teach · 2025-09-15 | Ffrct | $1,275 |
| Heartflow | Paid to speak or teach · 2025-09-15 | Ffrct | $1,488 |
| Heartflow | Paid to speak or teach · 2025-09-15 | Ffrct | $2,125 |
| Amarin Pharma | Meals · 2025-09-11 | Vascepa | $90 |
| Amarin Pharma | Travel · 2025-09-11 | Vascepa | $89 |
| Corcept Therapeutics | Travel · 2025-09-10 | Korlym | $325 |
| Amgen | Meals · 2025-09-10 | Repatha | $124 |
| Merck Sharp & Dohme | Consulting · 2025-09-10 | None | $1,908 |
| Heartflow | Meals · 2025-09-09 | Ffrct | $160 |
| Regeneron Healthcare Solutions | Travel · 2025-09-05 | Evkeeza | $95 |
| Regeneron Healthcare Solutions | Travel · 2025-09-05 | Evkeeza | $70 |
| Regeneron Healthcare Solutions | Meals · 2025-09-05 | Evkeeza | $18 |
| Heartflow | Travel · 2025-09-05 | Ffrct | $173 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-09-02 | None | $309 |
| Merck Sharp & Dohme | Travel · 2025-09-02 | None | $336 |
| Merck Sharp & Dohme | Meals · 2025-09-02 | None | $43 |
| Merck Sharp & Dohme | Meals · 2025-09-02 | None | $36 |
| Merck Sharp & Dohme | Travel · 2025-09-01 | None | $336 |
| Heartflow | Travel · 2025-08-31 | Ffrct | $364 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-08-29 | None | $64 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-08-29 | None | $181 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-08-27 | Lokelma | $4,300 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-08-27 | None | $317 |
| Amgen | Paid to speak or teach · 2025-08-27 | Repatha | $2,800 |
| Amgen | Paid to speak or teach · 2025-08-27 | Repatha | $467 |
| Merck Sharp & Dohme | Consulting · 2025-08-27 | None | $640 |
| Amgen | Travel · 2025-08-26 | Repatha | $182 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-08-22 | Evkeeza | $4,697 |
| Amgen | Meals · 2025-08-21 | Repatha | $144 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-08-20 | Lokelma | $236 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-20 | Lokelma | $121 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-08-20 | Lokelma | $128 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-08-20 | Lokelma | $152 |
| Regeneron Healthcare Solutions | Meals · 2025-08-19 | Evkeeza | $34 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-08-15 | Evkeeza | $2,135 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-08-15 | Evkeeza | $2,135 |
| Boehringer Ingelheim Pharmaceuticals | Consulting · 2025-08-14 | None | $805 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-08-12 | Evkeeza | $4,697 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-12 | None | $35 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-08-12 | None | $140 |
| Boehringer Ingelheim Pharmaceuticals | Consulting · 2025-08-12 | None | $10,200 |
| Heartflow | Travel · 2025-08-12 | Ffrct | $190 |
| Regeneron Healthcare Solutions | Meals · 2025-08-08 | Evkeeza | $29 |
| Corcept Therapeutics | Paid to speak or teach · 2025-08-06 | Korlym | $3,240 |
| Heartflow | Travel · 2025-08-05 | Ffrct | $199 |
| AGEPHA Pharma FZ | Meals · 2025-08-01 | Lodoco | $24 |
| Corcept Therapeutics | Meals · 2025-07-31 | Korlym | $80 |
| Corcept Therapeutics | Meals · 2025-07-31 | Korlym | $138 |
| Corcept Therapeutics | Meals · 2025-07-31 | Korlym | $33 |
| Corcept Therapeutics | Meals · 2025-07-31 | Korlym | $69 |
| Abbvie | Consulting · 2025-07-30 | None | $5,600 |
| Abbvie | Consulting · 2025-07-30 | None | $400 |
| Heartflow | Paid to speak or teach · 2025-07-29 | Ffrct | $4,200 |
| Heartflow | Paid to speak or teach · 2025-07-29 | Ffrct | $2,100 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-17 | None | $59 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-17 | None | $17 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-17 | None | $14 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-17 | None | $55 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-07-17 | None | $251 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-07-15 | Evkeeza | $5,124 |
| Abbvie | Travel · 2025-07-14 | None | $106 |
| Regeneron Healthcare Solutions | Travel · 2025-07-12 | Evkeeza | $349 |
| Regeneron Healthcare Solutions | Travel · 2025-07-11 | Evkeeza | $6 |
| Regeneron Healthcare Solutions | Travel · 2025-07-11 | Evkeeza | $9 |
| Regeneron Healthcare Solutions | Travel · 2025-07-11 | Evkeeza | $43 |
| Regeneron Healthcare Solutions | Meals · 2025-07-11 | Evkeeza | $125 |
| Heartflow | Travel · 2025-07-09 | Ffrct | $282 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-07-08 | Kerendia | $429 |
| Heartflow | Meals · 2025-07-08 | Ffrct | $148 |
| Amgen | Travel · 2025-07-01 | Repatha | $25 |
| Amgen | Paid to speak or teach · 2025-07-01 | Repatha | $2,800 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-06-27 | Evkeeza | $2,135 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-06-27 | Kerendia | $225 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-06-27 | Kerendia | $4,147 |
| Amgen | Meals · 2025-06-26 | Repatha | $131 |
| Heartflow | Meals · 2025-06-26 | Ffrct | $343 |
| Boston Scientific | Meals · 2025-06-25 | General - Ultrasound | $174 |
| Novo Nordisk | Paid to speak or teach · 2025-06-25 | Wegovy | $1,168 |
| Amarin Pharma | Paid to speak or teach · 2025-06-25 | Vascepa | $5,720 |
| Boehringer Ingelheim Pharmaceuticals | Paid to speak or teach · 2025-06-24 | Jardiance | $1,200 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-06-23 | Kerendia | $162 |
| Abbvie | Meals · 2025-06-19 | None | $15 |
| Abbvie | Meals · 2025-06-19 | None | $55 |
| Abbvie | Travel · 2025-06-18 | None | $276 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-06-18 | Kerendia | $4,147 |
| Amgen | Paid to speak or teach · 2025-06-17 | Repatha | $467 |
| Amgen | Paid to speak or teach · 2025-06-17 | Repatha | $2,800 |
| Amgen | Travel · 2025-06-16 | Repatha | $196 |
| Heartflow | Consulting · 2025-06-16 | Ffrct | $600 |
| Heartflow | Paid to speak or teach · 2025-06-16 | Ffrct | $3,900 |
| Heartflow | Consulting · 2025-06-16 | Ffrct | $600 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-14 | Kerendia | $122 |
| Medtronic | Meals · 2025-06-13 | Symplicity G3 | $167 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-06-13 | None | $147 |
| Regeneron Healthcare Solutions | Travel · 2025-06-12 | Evkeeza | $193 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-06-12 | None | $195 |
| Regeneron Healthcare Solutions | Travel · 2025-06-11 | Evkeeza | $258 |
| Regeneron Healthcare Solutions | Travel · 2025-06-11 | Evkeeza | $214 |
| Pfizer | Meals · 2025-06-10 | Vyndaqel | $15 |
| Amarin Pharma | Meals · 2025-06-10 | Vascepa | $113 |
| Amarin Pharma | Travel · 2025-06-10 | Vascepa | $164 |
| Amarin Pharma | Meals · 2025-06-10 | Vascepa | $17 |
| Amarin Pharma | Travel · 2025-06-10 | Vascepa | $423 |
| Amarin Pharma | Travel · 2025-06-10 | Vascepa | $132 |
| Novo Nordisk | Meals · 2025-06-07 | None | $125 |
| AGEPHA Pharma FZ | Consulting · 2025-06-06 | Lodoco | $4,500 |
| Amgen | Meals · 2025-06-05 | Repatha | $121 |
| Heartflow | Paid to speak or teach · 2025-06-05 | Ffrct | $3,000 |
| Heartflow | Consulting · 2025-06-05 | Ffrct | $1,200 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-06-04 | Evkeeza | $854 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-06-04 | Evkeeza | $4,697 |
| Novo Nordisk | Consulting · 2025-06-03 | None | $3,925 |
| Heartflow | Travel · 2025-06-02 | Ffrct | $148 |
| Heartflow | Travel · 2025-06-02 | Ffrct | $123 |
| Regeneron Healthcare Solutions | Meals · 2025-05-30 | Evkeeza | $49 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-05-28 | Evkeeza | $4,697 |
| Lilly USA | Paid to speak or teach · 2025-05-27 | Zepbound | $1,600 |
| Heartflow | Meals · 2025-05-27 | Ffrct | $190 |
| Regeneron Healthcare Solutions | Travel · 2025-05-23 | Evkeeza | $113 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-23 | Kerendia | $149 |
| Novartis Pharmaceuticals | Meals · 2025-05-22 | Leqvio | $125 |
| Regeneron Healthcare Solutions | Meals · 2025-05-22 | Evkeeza | $36 |
| Boehringer Ingelheim Pharmaceuticals | Paid to speak or teach · 2025-05-22 | Jardiance | $1,200 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-05-21 | Kerendia | $157 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-05-21 | Kerendia | $4,147 |
| Novo Nordisk | Consulting · 2025-05-19 | None | $1,570 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-16 | Kerendia | $125 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-16 | Kerendia | $125 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-05-16 | Kerendia | $4,524 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-05-16 | Kerendia | $4,147 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-05-14 | Kerendia | $3,016 |
| Heartflow | Travel · 2025-05-14 | Ffrct | $1,118 |
| Regeneron Healthcare Solutions | Meals · 2025-05-13 | Evkeeza | $118 |
| Heartflow | Paid to speak or teach · 2025-05-12 | Ffrct | $7,200 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-05-10 | Kerendia | $225 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-05-09 | Evkeeza | $4,697 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-05-09 | Evkeeza | $5,124 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-08 | Kerendia | $119 |
| Regeneron Healthcare Solutions | Meals · 2025-05-07 | Evkeeza | $29 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-07 | Kerendia | $34 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-07 | Kerendia | $22 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-05-07 | Kerendia | $4,147 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-05-07 | Kerendia | $197 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-05-02 | Kerendia | $729 |
| Cleerly | Meals · 2025-05-02 | Cleerly Ischemia | $85 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-01 | Kerendia | $24 |
| Boehringer Ingelheim Pharmaceuticals | Paid to speak or teach · 2025-04-29 | Jardiance | $1,200 |
| Heartflow | Travel · 2025-04-29 | Ffrct | $1,285 |
| Lilly USA | Paid to speak or teach · 2025-04-28 | Zepbound | $3,200 |
| Lilly USA | Paid to speak or teach · 2025-04-28 | Zepbound | $2,000 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-04-25 | Kerendia | $138 |
| Novo Nordisk | Paid to speak or teach · 2025-04-24 | Wegovy | $6,869 |
| Novo Nordisk | Travel · 2025-04-24 | Wegovy | $159 |
| Novo Nordisk | Meals · 2025-04-24 | Wegovy | $125 |
| Lilly USA | Travel · 2025-04-23 | None | $780 |
| Lilly USA | Meals · 2025-04-23 | Zepbound | $104 |
| Novo Nordisk | Paid to speak or teach · 2025-04-22 | Wegovy | $6,084 |
| Novo Nordisk | Travel · 2025-04-22 | Wegovy | $136 |
| Novo Nordisk | Meals · 2025-04-22 | Wegovy | $124 |
| Novartis Pharmaceuticals | Meals · 2025-04-21 | Leqvio | $32 |
| Boehringer Ingelheim Pharmaceuticals | Paid to speak or teach · 2025-04-18 | Jardiance | $3,300 |
| Heartflow | Travel · 2025-04-18 | Ffrct | $138 |
| Heartflow | Travel · 2025-04-18 | Ffrct | $128 |
| Lilly USA | Travel · 2025-04-17 | Zepbound | $141 |
| Novo Nordisk | Meals · 2025-04-17 | Wegovy | $144 |
| Novo Nordisk | Paid to speak or teach · 2025-04-17 | Wegovy | $8,046 |
| Novo Nordisk | Travel · 2025-04-17 | Wegovy | $108 |
| Novo Nordisk | Travel · 2025-04-17 | Wegovy | $503 |
| Novo Nordisk | Travel · 2025-04-15 | Wegovy | $118 |
| Novo Nordisk | Paid to speak or teach · 2025-04-15 | Wegovy | $5,103 |
| Novo Nordisk | Meals · 2025-04-15 | Wegovy | $119 |
| Lilly USA | Paid to speak or teach · 2025-04-11 | Zepbound | $1,200 |
| Lilly USA | Paid to speak or teach · 2025-04-11 | Zepbound | $3,200 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-04-11 | Evkeeza | $8,540 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-04-10 | Kerendia | $439 |
| Boehringer Ingelheim Pharmaceuticals | Travel · 2025-04-09 | Jardiance | $143 |
| Cleerly | Travel · 2025-04-08 | None | $205 |
| Cleerly | Consulting · 2025-04-08 | None | $2,500 |
| Novo Nordisk | Paid to speak or teach · 2025-04-02 | Wegovy | $5,103 |
| Novo Nordisk | Travel · 2025-04-02 | Wegovy | $8 |
| Novo Nordisk | Travel · 2025-04-02 | Wegovy | $34 |
| Novo Nordisk | Meals · 2025-04-02 | Wegovy | $113 |
| Abbvie | Consulting · 2025-04-02 | None | $400 |
| Amgen | Travel · 2025-03-31 | Repatha | $10 |
| Amgen | Travel · 2025-03-31 | Repatha | $11 |
| Amgen | Paid to speak or teach · 2025-03-31 | Repatha | $2,800 |
| Bayer Healthcare Pharmaceuticals | Consulting · 2025-03-29 | Kerendia | $1,808 |
| Merck Sharp & Dohme | Meals · 2025-03-29 | None | $55 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-27 | Jardiance | $124 |
| Amgen | Meals · 2025-03-26 | Repatha | $118 |
| Amarin Pharma | Paid to speak or teach · 2025-03-25 | Vascepa | $2,600 |
| Amgen | Travel · 2025-03-24 | Repatha | $170 |
| Novo Nordisk | Paid to speak or teach · 2025-03-21 | Wegovy | $8,439 |
| Novo Nordisk | Travel · 2025-03-21 | Wegovy | $825 |
| Novo Nordisk | Meals · 2025-03-21 | Wegovy | $121 |
| Novo Nordisk | Travel · 2025-03-21 | Wegovy | $435 |
| Amgen | Paid to speak or teach · 2025-03-21 | Repatha | $2,800 |
| Amgen | Paid to speak or teach · 2025-03-21 | Repatha | $467 |
| Heartflow | Travel · 2025-03-21 | Ffrct | $624 |
| Heartflow | Travel · 2025-03-21 | Ffrct | $624 |
| Amarin Pharma | Meals · 2025-03-21 | Vascepa | $15 |
| Amarin Pharma | Travel · 2025-03-21 | Vascepa | $159 |
| Amarin Pharma | Travel · 2025-03-21 | Vascepa | $316 |
| Amarin Pharma | Travel · 2025-03-21 | Vascepa | $26 |
| Heartflow | Meals · 2025-03-19 | Ffrct | $167 |
| Amgen | Meals · 2025-03-18 | Repatha | $148 |
| Lilly USA | Paid to speak or teach · 2025-03-17 | Zepbound | $2,800 |
| Lilly USA | Paid to speak or teach · 2025-03-17 | Zepbound | $3,200 |
| Lilly USA | Paid to speak or teach · 2025-03-17 | Zepbound | $3,200 |
| Amgen | Paid to speak or teach · 2025-03-14 | Repatha | $701 |
| Heartflow | Travel · 2025-03-14 | Ffrct | $229 |
| Heartflow | Paid to speak or teach · 2025-03-14 | Ffrct | $8,700 |
| Heartflow | Paid to speak or teach · 2025-03-14 | Ffrct | $4,200 |
| Heartflow | Paid to speak or teach · 2025-03-14 | Ffrct | $9,300 |
| Heartflow | Travel · 2025-03-14 | Ffrct | $118 |
| Lilly USA | Meals · 2025-03-13 | Zepbound | $118 |
| Lilly USA | Travel · 2025-03-13 | None | $228 |
| Lilly USA | Travel · 2025-03-13 | None | $126 |
| Lilly USA | Meals · 2025-03-13 | Zepbound | $22 |
| Lilly USA | Travel · 2025-03-13 | None | $158 |
| Lilly USA | Travel · 2025-03-13 | None | $245 |
| Lilly USA | Travel · 2025-03-13 | None | $210 |
| Heartflow | Travel · 2025-03-12 | Ffrct | $108 |
| Lilly USA | Paid to speak or teach · 2025-03-11 | Jardiance | $1,650 |
| Cleerly | Meals · 2025-03-06 | Cleerly Ischemia | $138 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-03-05 | Kerendia | $4,147 |
| Amgen | Meals · 2025-02-28 | Repatha | $4 |
| Amgen | Meals · 2025-02-28 | Repatha | $13 |
| Lilly USA | Meals · 2025-02-25 | Zepbound | $16 |
| Lilly USA | Meals · 2025-02-25 | Zepbound | $20 |
| Lilly USA | Travel · 2025-02-25 | Zepbound | $10 |
| Lilly USA | Travel · 2025-02-25 | Zepbound | $69 |
| Lilly USA | Meals · 2025-02-25 | Zepbound | $5 |
| Lilly USA | Travel · 2025-02-25 | Zepbound | $63 |
| Lilly USA | Paid to speak or teach · 2025-02-24 | Zepbound | $1,600 |
| Heartflow | Paid to speak or teach · 2025-02-24 | Ffrct | $4,200 |
| Heartflow | Consulting · 2025-02-24 | Ffrct | $300 |
| Heartflow | Travel · 2025-02-24 | Ffrct | $60 |
| Amgen | Travel · 2025-02-20 | Repatha | $42 |
| Amgen | Travel · 2025-02-20 | Repatha | $10 |
| Amarin Pharma | Paid to speak or teach · 2025-02-19 | Vascepa | $2,600 |
| Amgen | Paid to speak or teach · 2025-02-18 | Repatha | $2,800 |
| Amgen | Paid to speak or teach · 2025-02-18 | Repatha | $467 |
| Heartflow | Travel · 2025-02-13 | Ffrct | $45 |
| Heartflow | Meals · 2025-02-13 | Ffrct | $98 |
| Amgen | Meals · 2025-02-12 | Repatha | $124 |
| Regeneron Healthcare Solutions | Travel · 2025-02-11 | Evkeeza | $54 |
| Regeneron Healthcare Solutions | Travel · 2025-02-11 | Evkeeza | $55 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-02-11 | Evkeeza | $2,135 |
| Amgen | Paid to speak or teach · 2025-02-11 | Repatha | $2,800 |
| Heartflow | Meals · 2025-02-08 | Ffrct | $71 |
| Lilly USA | Paid to speak or teach · 2025-02-07 | Zepbound | $1,600 |
| Regeneron Healthcare Solutions | Travel · 2025-02-07 | None | $73 |
| Heartflow | Travel · 2025-02-06 | Ffrct | $45 |
| Lilly USA | Paid to speak or teach · 2025-02-05 | Zepbound | $8,000 |
| Amarin Pharma | Meals · 2025-02-05 | Vascepa | $125 |
| Amarin Pharma | Travel · 2025-02-05 | Vascepa | $150 |
| Regeneron Healthcare Solutions | Travel · 2025-02-04 | Evkeeza | $60 |
| Regeneron Healthcare Solutions | Travel · 2025-02-04 | Evkeeza | $151 |
| Regeneron Healthcare Solutions | Travel · 2025-02-04 | Evkeeza | $33 |
| Regeneron Healthcare Solutions | Travel · 2025-02-04 | Evkeeza | $65 |
| Regeneron Healthcare Solutions | Travel · 2025-02-04 | Evkeeza | $35 |
| Regeneron Healthcare Solutions | Meals · 2025-02-04 | Evkeeza | $70 |
| Regeneron Healthcare Solutions | Meals · 2025-02-04 | Evkeeza | $28 |
| Amgen | Meals · 2025-02-04 | Repatha | $17 |
| Amgen | Meals · 2025-02-04 | Repatha | $17 |
| Novo Nordisk | Consulting · 2025-02-03 | None | $1,570 |
| Novo Nordisk | Consulting · 2025-02-03 | None | $1,570 |
| AGEPHA Pharma FZ | Consulting · 2025-02-01 | Lodoco | $2,000 |
| Lilly USA | Travel · 2025-01-31 | None | $282 |
| Lilly USA | Paid to speak or teach · 2025-01-30 | Zepbound | $3,200 |
| Lilly USA | Paid to speak or teach · 2025-01-30 | Zepbound | $3,200 |
| Lilly USA | Paid to speak or teach · 2025-01-30 | Zepbound | $2,800 |
| Lilly USA | Paid to speak or teach · 2025-01-30 | Zepbound | $3,200 |
| Regeneron Healthcare Solutions | Travel · 2025-01-30 | Evkeeza | $5 |
| Regeneron Healthcare Solutions | Travel · 2025-01-30 | Evkeeza | $46 |
| Heartflow | Meals · 2025-01-30 | Ffrct | $169 |
| Heartflow | Travel · 2025-01-30 | Ffrct | $90 |
| Heartflow | Meals · 2025-01-30 | Ffrct | $39 |
| Heartflow | Travel · 2025-01-30 | Ffrct | $302 |
| Heartflow | Travel · 2025-01-30 | Ffrct | $186 |
| Heartflow | Travel · 2025-01-30 | Ffrct | $227 |
| Merck Sharp & Dohme | Consulting · 2025-01-29 | None | $3,815 |
| Lilly USA | Travel · 2025-01-28 | None | $199 |
| Lilly USA | Travel · 2025-01-28 | None | $279 |
| Lilly USA | Meals · 2025-01-28 | Zepbound | $1 |
| Lilly USA | Meals · 2025-01-28 | Zepbound | $126 |
| Lilly USA | Travel · 2025-01-28 | None | $367 |
| Lilly USA | Travel · 2025-01-28 | None | $590 |
| Lilly USA | Meals · 2025-01-28 | Zepbound | $21 |
| Lilly USA | Travel · 2025-01-28 | None | $234 |
| Lilly USA | Travel · 2025-01-28 | None | $50 |
| Lilly USA | Meals · 2025-01-28 | Zepbound | $17 |
| Lilly USA | Meals · 2025-01-28 | Zepbound | $1 |
| Pfizer | Meals · 2025-01-17 | Vyndaqel | $19 |
| Regeneron Healthcare Solutions | Meals · 2025-01-16 | Evkeeza | $39 |
| Heartflow | Travel · 2025-01-11 | Ffrct | $450 |
| Novo Nordisk | Paid to speak or teach · 2025-01-01 | Wegovy | $2,002 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-01-01 | None | $5,124 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-01-01 | None | $2,135 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $574,074
| Novo Nordisk | Wegovy | $99,592 | 38 payments
|
| Lilly USA | Zepbound | $72,135 | 60 payments
|
| Lexicon Pharmaceuticals | None | $52,169 | 9 payments
|
| Amgen | Repatha | $50,232 | 58 payments
|
| Regeneron Healthcare Solutions | Evkeeza | $43,868 | 24 payments
|
| Esperion Therapeutics | Nexlizet | $42,984 | 34 payments
|
| Merck Sharp & Dohme | Verquvo | $37,799 | 26 payments
|
| Heartflow | Ffrct | $35,139 | 48 payments
|
| Janssen Pharmaceuticals | Xarelto | $29,926 | 23 payments
|
| Seqirus USA | None | $26,991 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $21,693 | 28 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $14,224 | 17 payments
|
| Novartis Pharmaceuticals | Leqvio | $10,420 | 10 payments
|
| Amarin Pharma | Vascepa | $8,167 | 5 payments
|
| Genentech | None | $6,192 | 3 payments
|
| Cleerly | Cleerly Ischemia | $5,373 | 5 payments
|
| Idorsia Pharmaceuticals US | Quviviq | $3,540 | 1 payment
|
| Canon Medical Informatics | Vitrea V-Score | $3,000 | 2 payments
|
| Corcept Therapeutics | Korlym | $2,545 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $2,539 | 3 payments
|
| Eli Lilly and | Jardiance | $1,800 | 1 payment
|
| FUKUDA DENSHI Co. | Vs-2000 | $1,500 | 1 payment
|
| Elucid Bioimaging | None | $1,200 | 1 payment
|
| United Imaging Healthcare North America | Next Generation Ct Systems | $812 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $150 | 1 payment
|
| Ge Healthcare | None | $67 | 2 payments
|
| Pfizer | Vyndaqel | $17 | 1 payment
|
2023: $407,316
| Merck Sharp & Dohme | Verquvo | $92,396 | 93 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $72,953 | 72 payments
|
| Novo Nordisk | Ozempic | $61,866 | 34 payments
|
| Regeneron Healthcare Solutions | Evkeeza | $47,926 | 40 payments
|
| Amgen | Repatha | $22,035 | 38 payments
|
| Novartis Pharmaceuticals | Leqvio | $18,687 | 22 payments
|
| Lilly USA | Jardiance | $16,718 | 17 payments
|
| Janssen Pharmaceuticals | Xarelto | $15,105 | 13 payments
|
| Amarin Pharma | Vascepa | $13,754 | 15 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $9,703 | 7 payments
|
| HeartFlow | Ffrct | $8,965 | 7 payments
|
| Renalytix AI | Kidneyintelx Blood Collection Convenience Kit | $6,000 | 2 payments
|
| Eli Lilly and | None | $6,000 | 4 payments
|
| Novo Nordisk AS | None | $5,550 | 2 payments
|
| Arineta | Spotlight | $4,355 | 1 payment
|
| Esperion Therapeutics | Nexlizet | $1,979 | 2 payments
|
| FUKUDA DENSHI Co. | Vs-2000 | $1,500 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $1,186 | 2 payments
|
| Lexicon Pharmaceuticals | Inpefa | $465 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $54 | 3 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $50 | 2 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $30 | 1 payment
|
| United Therapeutics | Tyvaso | $23 | 1 payment
|
| Pfizer | Vyndaqel | $15 | 1 payment
|
2022: $487,476
| Merck Sharp & Dohme | Verquvo | $105,849 | 101 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $90,867 | 86 payments
|
| Esperion Therapeutics | Nexlizet | $73,895 | 54 payments
|
| Novo Nordisk | Ozempic | $72,258 | 38 payments
|
| Janssen Pharmaceuticals | Xarelto | $48,906 | 43 payments
|
| Lilly USA | Jardiance | $18,000 | 14 payments
|
| Amgen | Repatha | $13,867 | 22 payments
|
| HeartFlow | Ffrct | $11,146 | 10 payments
|
| Amarin Pharma | Vascepa | $10,630 | 8 payments
|
| Regeneron Healthcare Solutions | Evkeeza | $9,457 | 8 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $9,353 | 16 payments
|
| Eli Lilly and | None | $5,570 | 4 payments
|
| Actelion Pharmaceuticals | None | $4,361 | 6 payments
|
| Elucid | Elucidvivo | $4,083 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $3,249 | 13 payments
|
| Kowa Pharmaceuticals America | Livalo | $3,231 | 2 payments
|
| GE HealthCare | None | $1,600 | 1 payment
|
| FUKUDA DENSHI Co. | Vs-2000 | $1,000 | 1 payment
|
| Pfizer | Vyndaqel | $60 | 3 payments
|
| Cook Medical | Advance | $41 | 2 payments
|
| Regeneron Pharmaceuticals | Evkeeza | $29 | 1 payment
|
| Astellas Pharma US | Lexiscan | $24 | 1 payment
|
2021: $558,227
| Esperion Therapeutics | Nexlizet | $147,953 | 108 payments
|
| Lilly USA | Trulicity | $123,675 | 90 payments
|
| Novo Nordisk | Ozempic | $90,130 | 43 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $63,246 | 64 payments
|
| Merck Sharp & Dohme | Verquvo | $43,740 | 32 payments
|
| Amgen | Repatha | $21,382 | 20 payments
|
| Amarin Pharma | Vascepa | $16,650 | 10 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $16,636 | 14 payments
|
| Regeneron Healthcare Solutions | Evkeeza | $12,137 | 8 payments
|
| Eli Lilly and | Jardiance | $6,000 | 2 payments
|
| FUKUDA DENSHI Co. | Vs-2000 | $5,750 | 2 payments
|
| Pfizer | Eliquis | $3,385 | 6 payments
|
| Kowa Pharmaceuticals America | Livalo | $3,352 | 4 payments
|
| Novartis Pharmaceuticals | Leqvio | $1,692 | 4 payments
|
| Ge Healthcare | None | $1,600 | 1 payment
|
| Astellas Pharma US | Lexiscan | $213 | 3 payments
|
| Abbott Laboratories | Quadra Assura Crt Defibrillator | $181 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $170 | 8 payments
|
| Regeneron Pharmaceuticals | Praluent | $122 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $66 | 4 payments
|
| Actelion Pharmaceuticals US | Uptravi | $60 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $27 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $23 | 1 payment
|
| Medtronic | Heartware Hvad | $20 | 1 payment
|
| Boston Scientific | General Atherectomy | $16 | 1 payment
|
2020: $407,997
| Lilly USA | Trulicity | $127,634 | 83 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $83,396 | 82 payments
|
| Amarin Pharma | Vascepa | $41,077 | 48 payments
|
| Esperion Therapeutics | Nexlizet | $35,706 | 32 payments
|
| Amgen | Repatha | $27,140 | 31 payments
|
| Pfizer | Eliquis | $25,622 | 39 payments
|
| Novo Nordisk | Ozempic | $19,538 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $15,901 | 21 payments
|
| Sanofi-Aventis U.S. | Multaq | $9,240 | 2 payments
|
| Novartis Pharmaceuticals | Pelacarsen | $6,086 | 2 payments
|
| Eli Lilly and | Jardiance | $5,700 | 2 payments
|
| Abbott Laboratories | None | $5,000 | 2 payments
|
| Janssen Pharmaceuticals | Invokana | $3,143 | 10 payments
|
| Medicure Pharma | Hmg-Coa Reductase Inhibitor | $1,500 | 1 payment
|
| Fukuda Denshi Co. | None | $750 | 1 payment
|
| HeartFlow | None | $503 | 3 payments
|
| Akcea Therapeutics | Tegsedi | $36 | 1 payment
|
| Boston Scientific | Watchman | $25 | 1 payment
|
2019: $640,390
| Amarin Pharma | Vascepa | $117,265 | 123 payments
|
| Sanofi-Aventis U.S. | Praluent | $96,098 | 76 payments
|
| Janssen Pharmaceuticals | Invokana | $89,041 | 89 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $85,529 | 60 payments
|
| Amgen | Repatha | $76,397 | 97 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $70,793 | 67 payments
|
| Pfizer | Eliquis | $45,683 | 52 payments
|
| Lilly USA | Jardiance | $27,237 | 35 payments
|
| Regeneron Healthcare Solutions | Praluent | $12,257 | 25 payments
|
| Novo Nordisk | Tresiba | $8,099 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $7,250 | 6 payments
|
| Medicure Pharma | Zypitamag (Pitavastatin) | $3,000 | 1 payment
|
| Boehringer Ingelheim International GmbH | Jardiance | $1,107 | 10 payments
|
| Abbott Laboratories | Quadra Assura Crt Defibrillator | $197 | 2 payments
|
| HeartFlow | None | $157 | 3 payments
|
| Ge Healthcare | None | $112 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $58 | 3 payments
|
| Actelion Pharmaceuticals US | Uptravi | $38 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $24 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $20 | 1 payment
|
| Astellas Pharma US | Lexiscan | $18 | 1 payment
|
| Teleflex | Catheter - Guideliner | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novo Nordisk Inc · Semaglutide and Atherosclerosis Progression in Dm · 2020 | Their institution | $530,394 |
| Eli Lilly and Company · 2024 | This clinician | $473,869 |
| Novartis Pharmaceuticals Corporation · Imaging Long/Term Study of Inclisiran on Atherosclerotic Disease (Iliad) Trial · 2025 | Their institution | $409,870 |
| Novo Nordisk Inc · Semaglutide and Atherosclerosis Progression in Dm · 2019 | Their institution | $388,791 |
| GE HEALTHCARE · 20hc-G-Cardiac Ct Deblooming · 2025 | Their institution | $314,881 |
| Novo Nordisk Inc · Semaglutide and Atherosclerosis Progression in Dm · 2022 | Their institution | $271,283 |
| Novo Nordisk Inc · Semaglutide and Atherosclerosis Progression in Dm · 2021 | Their institution | $222,226 |
| Amgen Inc. · 20170625-Vesalius - Cv · 2021 | Their institution | $218,110 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Multicenter Study To Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients (Victorion-1 Prevent) · 2024 | Their institution | $214,355 |
| Novartis Pharmaceuticals Corporation · A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase Iiib Study Evaluating the Effect of Inclisiran on Atherosclerotic Plaque Progression Assessed By Coronary Computed Tomography Angiography (Ccta) in Participants With A Diagnosis of Non-Obstructive Coronary Artery Disease Without Previous Cardiovascular Events (Victorion-Plaque) · 2024 | Their institution | $165,293 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empagliflozin and Heart Failure (Hfpef) · 2019 | Their institution | $163,669 |
| AstraZeneca Pharmaceuticals LP · Amethyst Congestive Heart Failure Chf Heart Failure Therapy Area Cardiovascular, Renal and Metabolism · 2021 | Their institution | $160,743 |
| GE Global Research an unincorporated business of GE Company · 2023 | Their institution | $157,252 |
| Amgen Inc. · Vesalius - Cv · 2020 | Their institution | $154,904 |
| AstraZeneca Pharmaceuticals LP · A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Medi5884 in Subjects With Prior Myocardial Infarction · 2023 | Their institution | $150,000 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Multicenter Study To Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients (Victorion-1 Prevent) · 2025 | Their institution | $127,322 |
| GE HEALTHCARE · 2024 | Their institution | $124,023 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Exercise Capacity Study in Hfpef · 2019 | Their institution | $123,150 |
| Amgen Inc. · Fourier Ole (Ph 4) · 2020 | Their institution | $116,006 |
| Novo Nordisk AS · 2019 | Their institution | $114,639 |
| Amgen Inc. · 20170625 Vesalius - Cv · 2023 | Their institution | $111,939 |
| Boehringer Ingelheim International GmbH · Empagliflozin and Heart Failure (Hfpef) · 2021 | Their institution | $106,483 |
| Novartis Pharmaceuticals Corporation · A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase Iiib Study Evaluating the Effect of Inclisiran on Atherosclerotic Plaque Progression Assessed By Coronary Computed Tomography Angiography (Ccta) in Participants With A Diagnosis of Non-Obstructive Coronary Artery Disease Without Previous Cardiovascular Events (Victorion-Plaque) · 2023 | Their institution | $104,420 |
| GE HEALTHCARE · Evaluation of Dl Based Cacs · 2023 | Their institution | $102,510 |
| Amgen Inc. · 20170625 Vesalius - Cv · 2024 | Their institution | $96,922 |
| Novartis Pharmaceuticals Corporation · Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) · 2023 | Their institution | $94,920 |
| Amgen Inc. · 20160250-Fourier Ole (Ph 4) · 2021 | Their institution | $87,802 |
| Cleerly, Inc. · Confirm2 · 2024 | Their institution | $86,869 |
| Novartis Pharmaceuticals Corporation · A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase Iiib Study Evaluating the Effect of Inclisiran on Atherosclerotic Plaque Progression Assessed By Coronary Computed Tomography Angiography (Ccta) in Participants With A Diag · 2025 | Their institution | $85,603 |
| AstraZeneca Pharmaceuticals LP · An International, Multicentre, Parallel-Group, Randomised, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction (Hfpef) Short Title Determine-Preserved Dapagliflozin Effect on Exercise Capacity Using A 6-Minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction · 2020 | Their institution | $75,625 |
| Boehringer Ingelheim International GmbH · Empagliflozin and Heart Failure (Hfref) · 2020 | Their institution | $69,434 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind Placebocontrolled 26week Multicenter Study With A 78week Extension To Evaluate the Efficacy and Safety of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Mo · 2020 | Their institution | $67,610 |
| Novo Nordisk AS · Wegovy · 2023 | Their institution | $66,355 |
| HEARTFLOW, INC. · 100 Analysis : 200 Ffrct Analysis : 400 Clinical Studies : 442 Ffrct Acp · 2022 | Their institution | $64,800 |
| Amgen Inc. · A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction Or Stroke · 2025 | Their institution | $64,576 |
| Novo Nordisk AS · 2020 | Their institution | $63,074 |
| Boehringer Ingelheim International GmbH · Empagliflozin and Heart Failure (Hfref) · 2019 | Their institution | $63,000 |
| Amgen Inc. · Vesalius-Cv · 2019 | Their institution | $61,512 |
| Boehringer Ingelheim International GmbH · Empagliflozin and Heart Failure (Hfpef) · 2019 | Their institution | $60,259 |
| Amgen Inc. · Fourier Ole (Ph 4) · 2019 | Their institution | $58,145 |
| Amarin Pharma Inc. · Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy · 2019 | Their institution | $57,524 |
| Novartis Pharmaceuticals Corporation · Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) · 2024 | Their institution | $56,049 |
| Novo Nordisk AS · 2021 | Their institution | $55,484 |
| Boehringer Ingelheim International GmbH · Empagliflozin and Heart Failure (Hfpef) · 2020 | Their institution | $54,154 |
| Novartis Pharmaceuticals Corporation · Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) · 2022 | Their institution | $52,413 |
| Eli Lilly and Company · 2023 | This clinician | $52,097 |
| GE HEALTHCARE · Converge Registry · 2020 | Their institution | $51,672 |
| GE HEALTHCARE · Evaluation of Dl Based Calcium Score · 2022 | Their institution | $51,255 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empagliflozin and Heart Failure (Hfref) · 2019 | Their institution | $47,779 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Exercise Capacity Study in Hfref · 2019 | Their institution | $47,767 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind Placebocontrolled 26week Multicenter Study With A 78week Extension To Evaluate the Efficacy and Safety of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Mo · 2019 | Their institution | $46,205 |
| Novartis Pharmaceuticals Corporation · A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive Ldl-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome · 2022 | Their institution | $46,100 |
| Novo Nordisk AS · Wegovy · 2022 | Their institution | $44,008 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Exercise Capacity Study in Hfpef · 2020 | Their institution | $41,710 |
| Boehringer Ingelheim International GmbH · Empa-Kidney · 2019 | Their institution | $41,380 |
| AstraZeneca Pharmaceuticals LP · Randomized Double Blind Placebo Controlled Parallel Group Multicenter Phase 3 Study To Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate To Very Severe Chronic Obstructive Pulmonary Disease Copd · 2025 | Their institution | $40,900 |
| Novartis Pharmaceuticals Corporation · A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase Iiib Study Evaluating the Effect of Inclisiran on Atherosclerotic Plaque Progression Assessed By Coronary Computed Tomography Angiography (Ccta) in Participants With A Diag · 2022 | Their institution | $39,688 |
| Novartis Pharmaceuticals Corporation · A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive Ldl-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome · 2023 | Their institution | $39,412 |
| AstraZeneca Pharmaceuticals LP · Realize-K Phase IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating Sodium Zirconium Cyclosilicate (Szc) for the Management of Hyperkalemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease and Receiving Spironolactone · 2022 | Their institution | $36,252 |
| AstraZeneca Pharmaceuticals LP · An International, Multicentre, Parallel-Group, Randomised, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Reduced Ejection Fraction (Hfref) Short Title Determine-Reduced Dapagliflozin Effect on Exercise Capacity Using A 6-Minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction · 2020 | Their institution | $36,242 |
| Ionis Pharmaceuticals, Inc. · Is354cs9 · 2025 | Their institution | $34,219 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes · 2019 | Their institution | $33,566 |
| Amgen Inc. · Budoff: Fracture Risk and Fracture Predictors in Type 2 Diabetes Mellitus · 2020 | Their institution | $33,193 |
| Novo Nordisk AS · Rybelsus · 2020 | Their institution | $31,712 |
| Merck Sharp & Dohme LLC · A Pivotal Phase 3 Randomized, Placebo-Controlled Clinical Study To Evaluate the Efficacy and Safety of the Sgc Stimulator Vericiguat,Mk-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction · 2023 | Their institution | $31,416 |
| AstraZeneca Pharmaceuticals LP · An International, Multicentre, Parallel-Group, Randomised, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Reduced Ejection Fraction (Hfref) Short Title Determine-Reduced Dapagliflozin Effect on Exercise Capacity Using A 6-Minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction · 2019 | Their institution | $30,747 |
| Boehringer Ingelheim International GmbH · Empa-Kidney · 2021 | Their institution | $30,650 |
| AstraZeneca Pharmaceuticals LP · Amethyst Congestive Heart Failure Chf Heart Failure Therapy Area Cardiovascular, Renal and Metabolism · 2022 | Their institution | $29,112 |
| HEARTFLOW, INC. · 100 Analysis : 200 Ffrct Analysis : 400 Clinical Studies : 424 Precise · 2021 | Their institution | $28,641 |
| AstraZeneca Pharmaceuticals LP · An International, Multicentre, Parallel-Group, Randomised, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction (Hfpef) Short Title Determine-Preserved Dapagliflozin Effect on Exercise Capacity Using A 6-Minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction · 2019 | Their institution | $28,292 |
| Novo Nordisk AS · Rybelsus · 2021 | Their institution | $27,673 |
| Boehringer Ingelheim International GmbH · Empagliflozin and Heart Failure (Hfref) · 2021 | Their institution | $26,508 |
| GE HEALTHCARE · Evaluation of Deep Learning-Based Calcium Scoring Software · 2021 | Their institution | $25,628 |
| Amgen Inc. · 20170625 Vesalius - Cv · 2022 | Their institution | $25,358 |
| AstraZeneca Pharmaceuticals LP · A Phase 3,Randomised,Double Blind,Active Controlled Study To Assess the Efficacy,Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease Ckd Progression in Participants With Ckd and High Blood Pressure · 2024 | Their institution | $25,250 |
| Novo Nordisk AS · Rybelsus · 2022 | Their institution | $24,979 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empa-Kidney · 2019 | Their institution | $24,398 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empagliflozin and Heart Failure (Hfpef) · 2020 | Their institution | $24,398 |
| Novo Nordisk AS · Rybelsus · 2024 | Their institution | $24,292 |
| Merck Sharp & Dohme LLC · A Pivotal Phase 3 Randomized, Placebo-Controlled Clinical Study To Evaluate the Efficacy and Safety of the Sgc Stimulator Vericiguat,Mk-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction · 2024 | Their institution | $23,141 |
| Novo Nordisk AS · Rybelsus · 2023 | Their institution | $22,640 |
| Novo Nordisk Inc · Ozempic · 2024 | Their institution | $21,852 |
| Novartis Pharmaceuticals Corporation · An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials To Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated Ldl-C · 2022 | Their institution | $21,347 |
| Bayer HealthCare Pharmaceuticals Inc. · A Multicenter Randomized Double-Blind Parallel-Group Placebo-Controlled Study To Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (Nyha II-IV) and Left Ventricular Ejection Fraction = 40% (Lvef = 40%) · 2021 | Their institution | $21,146 |
| Novartis Pharmaceuticals Corporation · Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) · 2025 | Their institution | $20,737 |
| AstraZeneca Pharmaceuticals LP · A Phase III Randomised Double Blind Placebocontrolled Parallel Group Study To Assess the Effect of Azd0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease Or at Risk for A First Atherosclerotic Cardiovascular Disease Event · 2025 | Their institution | $19,100 |
| Amarin Pharma Inc. · A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate the Effect of Amr101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease Or at High Risk for Cardio · 2019 | Their institution | $18,649 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empa Kidney · 2022 | Their institution | $18,298 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empa-Kidney · 2021 | Their institution | $18,298 |
| Novo Nordisk Inc · Rybelsus · 2020 | This clinician | $18,182 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empagliflozin and Heart Failure (Hfref) · 2020 | Their institution | $17,282 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes Post Worsening Heart Failure · 2019 | Their institution | $17,168 |
| Merck Sharp & Dohme LLC · A Pivotal Phase 3 Randomized, Placebo-Controlled Clinical Study To Evaluate the Efficacy and Safety of the Sgc Stimulator Vericiguat,Mk-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction · 2022 | Their institution | $16,525 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Exercise Capacity Study in Hfref · 2020 | Their institution | $16,018 |
| Bayer Healthcare Pharmaceuticals Inc. · Bay 948862, A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (Nyha II-IV) and Left Ventricular Ejection Fracti · 2024 | Their institution | $14,766 |
| Novo Nordisk AS · Ozempic · 2021 | Their institution | $13,462 |
| Novartis Pharma AG · Ckjx839d12303 · 2023 | This clinician | $13,200 |
| Boehringer Ingelheim International GmbH · Empa-Kidney · 2020 | Their institution | $13,000 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empa-Kidney · 2020 | Their institution | $12,199 |
| Bayer Healthcare Pharmaceuticals Inc. · A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (Nyha II-IV) and Left Ventricular Ejection Fraction = 40% (Lv · 2025 | Their institution | $12,095 |
| Novo Nordisk AS · Ozempic · 2024 | Their institution | $12,076 |
| Bayer HealthCare Pharmaceuticals Inc. · Bay94-8862 Lcm Hfmr/Pef (Ef 40%) · 2022 | Their institution | $12,020 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes Post Worsening Heart Failure · 2020 | Their institution | $11,818 |
| Novo Nordisk AS · Rybelsus · 2025 | Their institution | $11,512 |
| Novartis Pharmaceuticals Corporation · An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials To Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated Ldl-C · 2020 | Their institution | $10,603 |
| Canon Medical Informatics, Inc. · Cardiac Analysis · 2025 | This clinician | $10,000 |
| Novo Nordisk AS · Ozempic · 2020 | Their institution | $9,465 |
| Novo Nordisk AS · Ozempic · 2023 | Their institution | $9,440 |
| Merck Sharp & Dohme LLC · A Pivotal Phase 3 Randomized, Placebo-Controlled Clinical Study To Evaluate the Efficacy and Safety of the Sgc Stimulator Vericiguat,Mk-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction · 2025 | Their institution | $9,108 |
| AstraZeneca Pharmaceuticals LP · An International, Multicentre, Parallel-Group, Randomised, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Reduced Ejection Fraction (Hfref) Short Title Determine-Reduced Dapagliflozin Effect on Exercise Capacity Using A 6-Minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction · 2021 | Their institution | $9,041 |
| AstraZeneca Pharmaceuticals LP · An International, Multicentre, Parallel-Group, Randomised, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction (Hfpef) Short Title Determine-Preserved Dapagliflozin Effect on Exercise Capacity Using A 6-Minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction · 2021 | Their institution | $9,012 |
| AstraZeneca Pharmaceuticals LP · Realize-K Phase IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating Sodium Zirconium Cyclosilicate (Szc) for the Management of Hyperkalemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease and Receiving Spironolactone · 2023 | Their institution | $8,748 |
| Novartis Pharmaceuticals Corporation · An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials To Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated Ldl-C · 2021 | Their institution | $8,603 |
| Novo Nordisk AS · Ozempic · 2022 | Their institution | $8,476 |
| Boehringer Ingelheim International GmbH · Empa Kidney · 2022 | Their institution | $8,060 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Exercise Capacity Study in Hfpef · 2019 | Their institution | $7,624 |
| Bayer Healthcare Pharmaceuticals Inc. · Bay94-8862 Lcm Hfmr/Pef (Ef 40%) · 2023 | Their institution | $6,913 |
| AstraZeneca UK Limited · Realize-K Phase IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating Sodium Zirconium Cyclosilicate (Szc) for the Management of Hyperkalemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease and Receiving Spironolactone · 2022 | Their institution | $6,802 |
| Novartis Pharmaceuticals Corporation · A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive Ldl-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome · 2024 | Their institution | $6,235 |
| Novartis Pharma AG · Ckjx839d12303 · 2025 | This clinician | $5,434 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empagliflozin and Heart Failure (Hfpef) · 2021 | Their institution | $5,083 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Exercise Capacity Study in Hfref · 2019 | Their institution | $4,981 |
| Boehringer Ingelheim International GmbH · Empa-Kidney · 2024 | Their institution | $4,800 |
| AstraZeneca Pharmaceuticals LP · A Phase 3,Randomised,Double Blind,Active Controlled Study To Assess the Efficacy,Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease Ckd Progression in Participants With Ckd and High Blood Pressure · 2025 | Their institution | $4,300 |
| Amgen Inc. · 20130295-Fourier Ole (Ph 4) · 2022 | Their institution | $3,570 |
| PFIZER INC. · Ertugliflozin Clinical Publication Program · 2020 | This clinician | $3,530 |
| Amgen Inc. · P4 Global Vesalius Real · 2025 | This clinician | $2,909 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes Post Worsening Heart Failure · 2021 | Their institution | $2,697 |
| Boehringer Ingelheim International GmbH · Empagliflozin and Heart Failure Hfpef · 2022 | Their institution | $2,685 |
| AstraZeneca Pharmaceuticals LP · Realize-K Phase IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating Sodium Zirconium Cyclosilicate (Szc) for the Management of Hyperkalemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease and Receiving Spironolactone · 2025 | Their institution | $2,579 |
| Boehringer Ingelheim International GmbH · Empa Kidney · 2023 | Their institution | $2,500 |
| Novartis Pharmaceuticals Corporation · An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials To Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated Ldl-C · 2023 | Their institution | $2,000 |
| Novo Nordisk AS · Nn9535-4321 & Ex9924-4473 · 2022 | This clinician | $1,794 |
| Cleerly, Inc. · Confirm2 · 2025 | Their institution | $1,464 |
| Novo Nordisk AS · Ozempic · 2025 | Their institution | $1,333 |
| Boehringer Ingelheim Canada Ltd.Ltee · Exercise Capacity Study in Hfpef · 2019 | Their institution | $1,137 |
| PFIZER INC. · Ertugliflozin Clinical Publication Program · 2021 | This clinician | $940 |
| Boehringer Ingelheim France S.A.S. · Exercise Capacity Study in Hfref · 2019 | Their institution | $798 |
| Cleerly, Inc. · Transform · 2025 | This clinician | $750 |
| AstraZeneca Pharmaceuticals LP · Realize-K Phase IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating Sodium Zirconium Cyclosilicate (Szc) for the Management of Hyperkalemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease and Receiving Spironolactone · 2024 | Their institution | $734 |
| Novartis Pharma AG · Ckjx839d12303 · 2024 | This clinician | $600 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Multicenter Study To Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients (Victorion-1 Prevent) · 2023 | Their institution | $387 |
| Bayer Healthcare Pharmaceuticals Inc. · Bay 948862, A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (Nyha II-IV) and Left Ventricular Ejection Fracti · 2025 | Their institution | $344 |
| Novartis Pharmaceuticals Corporation · A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive Ldl-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome · 2021 | Their institution | $325 |
| Eli Lilly and Company · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study To Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 Kg M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease · 2024 | Their institution | $187 |
| Amgen Inc. · P4 Global Vesalius Real · 2024 | This clinician | $80 |
| Novo Nordisk AS · Wegovy · 2023 | This clinician | $50 |
Professional record
- NPI
- 1811967433
- Licence
- CA G72496California G72496: Current · expires 2027-08-31
- Trained
- George Washington University School of Medicine, 1990 · 36 years ago
- Group
- Prohealth Partners, A Medical Group · United Medical Imaging Healthcare Inc · Clear Heart-Loveland LLC · Prairie Du Chien Memorial Hospital Association Inc
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G724960
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 21840 Normandie Ave, Ste. 700, Torrance, CA, 90502
- NPI first listed
- 2006-01-25
- NPI last updated
- 2010-02-24
This is when the NPI record was last certified, not a medical board exam.